Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, with multiple FDA-approved treatments and a robust pipeline targeting rare and severe conditions. The company has strong growth potential, ...
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
Here is how Alnylam Pharmaceuticals (ALNY) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure S...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that two new data sets from the HELIOS-B Phase 3 study of vut...
ALNY Down Despite Positive Data From Heart Disease Drug Study
Alnylam presents detailed data from the HELIOS-B study, seeking to expand Amvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy.
Alnylam shares slide after heart drug data fails to impress investors
Alnylam Pharmaceuticals' shares fell nearly 11% before the bell on Friday, after data for its closely watched heart drug fell short of heightened investor expectations.
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales.
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of a loss of $0.74 per share. This compares to loss of $2.21 per share a yea...
Alnylam Stock Is a Blockbuster Biopharma In the Making
Biopharmaceutical stock Alnylam Pharmaceuticals (NASDAQ: ALNY ) is riding a tsunami of hope that a treatment for a rare heart condition receives Food & Drug Administration approval. Although it has...
Alnylam Pharmaceuticals reports promising heart disease trial results
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug. Shares of the biopharmaceutical company ar...
The 'Undercovered' Dozen From June 1-6
The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered...
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corpora...
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Stre...
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.40 per share a year ago.
Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quar...
Related Companies